These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32075511)

  • 1. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance.
    Liu T; Shi N; Zhang S; Silverman GJ; Duan XW; Zhang S; Niu H
    Lupus; 2020 Mar; 29(3):273-282. PubMed ID: 32075511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus.
    Clement M; Charles N; Escoubet B; Guedj K; Chauveheid MP; Caligiuri G; Nicoletti A; Papo T; Sacre K
    J Autoimmun; 2015 Sep; 63():59-67. PubMed ID: 26183767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predominant Role of Immunoglobulin G in the Pathogenesis of Splenomegaly in Murine Lupus.
    Zhang Q; Xiang L; Zaman MH; Dong W; He G; Deng GM
    Front Immunol; 2019; 10():3020. PubMed ID: 32082297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus.
    Virdis A; Tani C; Duranti E; Vagnani S; Carli L; Kühl AA; Solini A; Baldini C; Talarico R; Bombardieri S; Taddei S; Mosca M
    Arthritis Res Ther; 2015 Oct; 17():277. PubMed ID: 26444671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
    Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine Autophagic Inhibition Rebalances Th17/Treg-Mediated Immunity and Ameliorates Systemic Lupus Erythematosus.
    An N; Chen Y; Wang C; Yang C; Wu ZH; Xue J; Ye L; Wang S; Liu HF; Pan Q
    Cell Physiol Biochem; 2017; 44(1):412-422. PubMed ID: 29141242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
    Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
    Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
    Olsen NJ; James JA; Arriens C; Ishimori ML; Wallace DJ; Kamen DL; Chong BF; Liao D; Chinchilli VM; Karp DR
    Trials; 2018 Dec; 19(1):694. PubMed ID: 30572906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease in systemic lupus erythematosus: an update.
    Liu Y; Kaplan MJ
    Curr Opin Rheumatol; 2018 Sep; 30(5):441-448. PubMed ID: 29870498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
    Bruce IN
    Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.
    Al Gadban MM; Alwan MM; Smith KJ; Hammad SM
    Clin Immunol; 2015 Apr; 157(2):133-44. PubMed ID: 25638414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.
    Stanic AK; Stein CM; Morgan AC; Fazio S; Linton MF; Wakeland EK; Olsen NJ; Major AS
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7018-23. PubMed ID: 16636270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA.
    Becker Y; Marcoux G; Allaeys I; Julien AS; Loignon RC; Benk-Fortin H; Rollet-Labelle E; Rauch J; Fortin PR; Boilard E
    Front Immunol; 2019; 10():1026. PubMed ID: 31134086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway.
    Deng GM; Liu L; Kyttaris VC; Tsokos GC
    J Immunol; 2010 Jun; 184(12):7154-61. PubMed ID: 20483718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus.
    Tumurkhuu G; Montano E; Jefferies C
    Curr Rheumatol Rep; 2019 Jul; 21(9):46. PubMed ID: 31338604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors.
    Sun J; Lundström SL; Zhang B; Zubarev RA; Steuer J; Gillgren P; Rahman M; Ajeganova S; Liu A; Frostegård J
    Atherosclerosis; 2018 Jan; 268():36-48. PubMed ID: 29175653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialic acid-binding immunoglobulin-type lectin H-positive plasmacytoid dendritic cells drive spontaneous lupus-like disease development in B6.Nba2 mice.
    Davison LM; Jørgensen TN
    Arthritis Rheumatol; 2015 Apr; 67(4):1012-22. PubMed ID: 25504931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.
    Voloshyna I; Teboul I; Littlefield MJ; Siegart NM; Turi GK; Fazzari MJ; Carsons SE; DeLeon J; Reiss AB
    Exp Biol Med (Maywood); 2016 Aug; 241(14):1611-9. PubMed ID: 27190277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of macrophage autophagy ameliorates activated lymphocytes-derived DNA induced murine lupus possibly via inhibition of proinflammatory cytokine production.
    Li B; Yue Y; Dong C; Shi Y; Xiong S
    Clin Exp Rheumatol; 2014; 32(5):705-14. PubMed ID: 25151985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus.
    Mok MY
    Int J Rheum Dis; 2015 Feb; 18(2):250-9. PubMed ID: 25639676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.